Condition

Triple Negative Breast Cancer (TNBC) clinical trials and research

• 42Clinical trials
• 12Countries

Newest Triple Negative Breast Cancer (TNBC) clinical trials

All recruiting trials (42)

• Personalized chemoimmunotherapy for early TNBC with high TILs (no anthracyclines upfront)

  This trial tests a 12-week, anthracycline-free neoadjuvant regimen of carboplatin, paclitaxel, and pembrolizumab in early-stage TNBC with high TILs to see if surgery outcomes are as good as historical regimens.

  Recruiting Phase 2 Medical University of South Carolina · Syracuse, New York and 1 other locations · NCT07743190

• BL-B01D1 plus PD-1 therapy vs nab-paclitaxel plus PD-1 therapy in untreated PD-L1-positive locally advanced or metastatic TNBC

  This phase 3 trial tests whether BL-B01D1 with a PD-1 antibody works better than nab-paclitaxel with a PD-1 antibody in women with newly treated, PD-L1-positive, locally advanced or metastatic triple-negative breast cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07729956

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Isunakinra Plus Pembrolizumab Neoadjuvant Therapy for TNBC

  This trial tests whether adding isunakinra to pembrolizumab-based neoadjuvant chemotherapy can help treat newly diagnosed, locally advanced triple-negative breast cancer.

  Recruiting Phase 1/2 University Health Network, Toronto · Toronto, Ontario · NCT07698106

• Self-amplifying RNA vaccine ITI-5000 for stage 2-3 TNBC (two-part study)

  This Phase 1 trial tests ITI-5000, a saRNA cancer vaccine, in adults with stage 2-3 triple-negative breast cancer who finished standard treatment, to see if it’s safe and can provoke an immune response, alone or with approved immunotherapy.

  Recruiting at 4 sites Phase 1 Immunomic Therapeutics, Inc. · Los Angeles, California and 3 other locations · NCT07652242

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

• Predicting immunochemotherapy response in early TNBC

  This study tests whether immune and molecular features in tumors can predict which women with early triple-negative breast cancer will completely respond to neoadjuvant immunochemotherapy.

  Recruiting Center Eugene Marquis · Rennes · NCT07570524

• First-in-human test of CT-202, a nectin-4 directed bispecific antibody for recurrent TNBC, colorectal and urothelial cancers

  This phase 1a/1b study tests CT-202 to see if it is safe and tolerable and to get early signals of activity in patients with nectin-4–expressing recurrent or metastatic TNBC, colorectal cancer, or urothelial cancer who have exhausted standard therapies.

  Recruiting at 6 sites Phase 1 Context Therapeutics Inc. · Wahroonga, New South Wales and 5 other locations · NCT07545122

• Dose-finding of EXS74539 (REC-4539) in select solid tumors

  This study will try different doses of the experimental drug EXS74539 in adults with select solid tumors to find a safe and tolerable dose.

  Recruiting at 3 sites Phase 1 Exscientia AI Limited · Los Angeles, California and 2 other locations · NCT07517198

• Nurse-led coping and support for TNBC patients

  This test will see if a nurse-led coping and supportive care program can help people with triple-negative breast cancer feel better during the transition from active treatment to surveillance.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07513311

• Dual-target CAR-NK therapy for advanced HER2-positive and triple-negative breast cancer

  This test gives a personalized dual-target CAR-NK cell infusion after short-course chemo to see if it is safe and can shrink tumors in adults with advanced HER2-positive or triple-negative breast cancer whose tumors express HER2, MUC1, or ROR1.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07486089

• Focused ultrasound (HIFU) with or without a PD‑1 immune drug before Abraxane and carboplatin in triple‑negative breast cancer

  This study will try focused ultrasound (HIFU) with or without the immune drug sintilimab before standard chemotherapy to see if people with early-stage triple‑negative breast cancer can achieve a complete tumor response.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07394387

• QL1706 with chemotherapy before surgery for triple-negative breast cancer

  This treatment tests whether giving QL1706 together with two sequential chemotherapy regimens before surgery helps people with stage II–III triple-negative breast cancer achieve a complete tumor response.

  Recruiting Phase 2 Affiliated Hospital of Nantong University · Nantong, Jiangsu · NCT07342283

• Preoperative chemotherapy with pembrolizumab and a low or high radiation boost for node-positive triple-negative breast cancer

  This study tests whether giving a low or high radiation boost together with preoperative chemotherapy and pembrolizumab can better activate the immune system in people with node‑positive triple‑negative breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07276880

• MR001 treatment for locally recurrent or metastatic triple-negative breast cancer.

  This will test MR001, a bispecific antibody, to see if it is safe and helps people with locally recurrent or metastatic TNBC who have progressed after prior therapy.

  Recruiting Phase 1/2 Shenzhen Majory Biotechnology Co., Ltd. · Beijing and 2 other locations · NCT07208149

• PQ203 for advanced solid tumors including triple negative breast cancer

  This trial will test whether once-weekly intravenous PQ203 is safe and tolerable in adults with advanced solid tumors, including triple negative breast cancer.

  Recruiting at 4 sites Phase 1 ProteinQure Inc. · Houston, Texas and 3 other locations · NCT07190469

• NRM-823 for advanced or metastatic refractory solid tumors

  This trial tests whether NRM-823 is safe and can help people with advanced or metastatic head and neck, esophageal, gastric, or related cancers.

  Recruiting at 18 sites Phase 1 Normunity AccelCo, Inc. · Denver, Colorado and 17 other locations · NCT07182149

• Treatment options after targeted therapy stops working in advanced breast cancer

  This study will see how well different treatments work for people with advanced breast cancer who have stopped responding to CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT07073755

• ctDNA surveillance with Dato-DXd for people with high-risk early triple-negative breast cancer and residual disease

  This study will test whether regular blood-based ctDNA monitoring can find tiny relapses in adults with stage II/III triple-negative breast cancer who have residual disease after neoadjuvant therapy and whether early treatment with Dato-DXd when ctDNA becomes positive can reduce recurrence.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07069595

• NKT5097 for adults with advanced or metastatic solid tumors.

  This trial tests an oral drug called NKT5097 in adults with advanced or metastatic solid tumors—especially certain breast cancers and tumors with CCNE1 amplification—to see if it is safe and shows anti‑tumor activity.

  Recruiting at 19 sites Phase 1 NiKang Therapeutics, Inc. · Duarte, California and 18 other locations · NCT07029399

• Nectin-4 targeted alpha radiotherapy [225Ac]Ac-AKY-1189 for advanced solid tumors

  This trial will try a Nectin‑4–targeted radioactive drug called [225Ac]Ac‑AKY‑1189 in adults with locally advanced or metastatic solid tumors, including certain bladder, breast, lung, and cervical cancers.

  Recruiting at 14 sites Phase 1 Aktis Oncology, Inc. · Duarte, California and 13 other locations · NCT07020117

• Impact of Timing on Immunotherapy for Triple Negative Breast Cancer

  This study is testing whether getting immunotherapy infusions in the morning or afternoon can improve treatment results for people with triple negative breast cancer.

  Recruiting Phase 1/2 Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. · Vila Nova de Gaia, Região · NCT06880029

• Treatment for brain metastases in triple-negative breast cancer using Ivonescimab and TROP2 ADC

  This study is testing a new combination treatment of ivonescimab and TROP2 antibody-drug conjugates for patients with triple-negative breast cancer that has spread to the brain to see if it helps them feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06793332

• Using Biolosion with standard therapy to treat triple-negative breast cancer

  This study is testing if adding a new oral probiotic called Biolosion to standard treatment can help women with locally advanced triple-negative breast cancer have better outcomes.

  Recruiting Phase 2 Sun Yat-sen University · Lanzhou, Gansu and 4 other locations · NCT06768931

• AK112 plus nab‑paclitaxel versus placebo plus nab‑paclitaxel for first‑line inoperable or metastatic triple‑negative breast cancer

  This trial tests whether adding AK112 to nab‑paclitaxel works better than placebo plus nab‑paclitaxel as first‑line treatment for adults with inoperable locally advanced or metastatic triple‑negative breast cancer.

  Recruiting Phase 3 Akeso · Beijing · NCT06767527

• Exploring the best treatment combinations for advanced triple-negative breast cancer

  This study is testing different combinations of radiation and immune therapy to see if they can help people with advanced triple-negative breast cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06735131

• ESG401 as first-line treatment for unresectable recurrent or metastatic triple-negative breast cancer.

  This trial will test whether ESG401 works and is safe as a first-line treatment for adults with unresectable recurrent or metastatic triple-negative breast cancer who have not had prior systemic therapy for advanced disease.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT06732323

• Testing new antibody drugs in advanced breast cancer patients who have used similar treatments before

  This study is testing new antibody drugs to see if they can help advanced breast cancer patients who have already tried similar treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06649331

• Combining All Trans Retinoic Acid with Toripalimab and Chemotherapy for Advanced Triple Negative Breast Cancer

  This study is testing whether a new combination of a vitamin A derivative, an immune therapy, and chemotherapy can help people with advanced triple negative breast cancer.

  Recruiting at 2 sites Phase 2 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT06636981

• Personalizing pembrolizumab for early triple-negative breast cancer patients with a complete response

  This trial will test whether people with early triple-negative breast cancer who have a complete response after pre-surgery treatment can safely stop pembrolizumab instead of continuing it for six more months.

  Recruiting at 2 sites Phase 3 Unicancer · Brussels and 1 other locations · NCT06606730

• MOv18 IgE treatment for platinum-resistant ovarian cancer

  This study is testing a new treatment called MOv18 IgE for people with platinum-resistant ovarian cancer to see if it can help shrink tumors and improve their health.

  Recruiting at 7 sites Phase 1 Epsilogen Ltd · Bristol and 6 other locations · NCT06547840

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

• Optimizing treatment for low stage triple-negative breast cancer patients

  This study is testing if patients with early-stage triple-negative breast cancer can skip chemotherapy after surgery and radiation if they have certain positive signs, to see how it affects their safety and quality of life.

  Recruiting at 18 sites The Netherlands Cancer Institute · Sittard-Geleen, Limburg and 27 other locations · NCT06476119

• Cell therapy for patients with advanced solid tumors

  This study is testing a new cell therapy using patients' own immune cells to see if it can help people with advanced solid tumors who haven't responded to other treatments.

  Recruiting Beijing Geekgene Technology Co., LTD · Zhengzhou, Henan · NCT06431100

• Evaluating Tenalisib for Metastatic Triple Negative Breast Cancer

  This study is testing a new drug called tenalisib to see if it can help people with metastatic triple negative breast cancer who have already tried other treatments.

  Recruiting at 7 sites Phase 2 Rhizen Pharmaceuticals SA · Vijayawada, Andhra Pradesh and 8 other locations · NCT06189209

• Assessing GTAEXS617 for advanced solid tumors

  This study is testing a new treatment called GTAEXS617 to see if it can help people with advanced solid tumors, like certain types of cancer, when other treatments haven't worked.

  Recruiting at 15 sites Phase 1/2 Exscientia AI Limited · Los Angeles, California and 14 other locations · NCT05985655

• Assessing safety and efficacy of new treatments for advanced solid tumors

  This study is testing two new treatments for patients with advanced solid tumors to see if they are safe and effective.

  Recruiting at 10 sites Phase 1/2 Lumara Bio Oncologics GmbH · Melbourne and 9 other locations · NCT05706129

• Precision neoadjuvant therapy for operable breast cancer

  This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05582499

• Evaluating JAB-2485 for Advanced Solid Tumors

  This study is testing a new drug called JAB-2485 to see if it is safe and can help adults with advanced solid tumors, like certain types of breast cancer and lung cancer, who have already tried other treatments.

  Recruiting at 8 sites Phase 1/2 Jacobio Pharmaceuticals Co., Ltd. · Detroit, Michigan and 7 other locations · NCT05490472

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

• Testing new treatments for triple negative breast cancer before and after surgery

  This study is testing new drugs before and after surgery to see if they can help people with triple negative breast cancer that hasn't completely gone away after chemotherapy.

  Recruiting at 3 sites Phase 2 Institute of Cancer Research, United Kingdom · Bournemouth, Dorset and 5 other locations · NCT03740893

Related topics

Quick answers

How many Triple Negative Breast Cancer (TNBC) clinical trials are recruiting right now?

42, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in China (16 trials), United States (16 trials), United Kingdom (5 trials), France (3 trials), Belgium (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1: 12, Phase 1/2: 7, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →